论文部分内容阅读
目的观察兰索拉唑能否缓解2型糖尿病(T2DM)患者口服二甲双胍引起的胃肠道不适,并探讨其对血糖、血清胃泌素(Gastrin)的影响及其可能的机制。方法将51例患者分为兰索拉唑组(n=26)和对照组(n=25),观察治疗前后空腹血糖(FBG)、糖化血红蛋白(HbA1C)、Gastrin、空腹胰岛素(FINS)、血脂、肝肾功及尿酸(UA)的变化。结果兰索拉唑组治疗后胃部不适症状明显减轻,有效缓解率95.0%,症状缓解时间(3.05±1.07)d;空腹胃泌素水平较治疗前升高[(158.26±11.85)vs(95.61±4.48)ng/L,P<0.05],治疗后FBG[(7.22±0.45)vs(7.70±0.29)mmol/L,P<0.05]和HbA1C[(7.28±0.76)%vs(7.85±0.05)%,P<0.05]均显著低于对照组;治疗前后,兰索拉唑组FBG的变化[(1.16±0.62)vs(0.51±0.45)mmol/L,P<0.05]及HbA1C的变化[(0.64±0.50)vs(0.33±0.43)mmol/L,P<0.05]均较对照组具有统计学意义(P<0.05)。相关回归分析显示,兰索拉唑组治疗后Gastrin升高与其HbA1C下降相关(r=-0.605,P<0.05)。结论兰索拉唑可以改善二甲双胍引起的胃部不适并能降低T2DM患者血糖水平,其作用可能与Gastrin的升高有关。
Objective To observe whether lansoprazole can relieve gastrointestinal discomfort caused by metformin oral administration in patients with type 2 diabetes mellitus (T2DM) and to explore its effect on blood glucose and serum gastrin and its possible mechanism. Methods 51 patients were divided into lansoprazole group (n = 26) and control group (n = 25). The levels of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1C), Gastrin, fasting insulin (FINS) , Liver and kidney function and uric acid (UA) changes. Results The gastric discomfort was relieved in the lansoprazole group with the effective remission rate of 95.0% and the symptom relief time of 3.05 ± 1.07 d. The fasting plasma gastrin level was higher than that before treatment [(158.26 ± 11.85) vs (95.61 (7.22 ± 0.45) vs (7.70 ± 0.29) mmol / L, P <0.05] and HbA1C [(7.28 ± 0.76)% vs (7.85 ± 0.05) %, P <0.05] were significantly lower than those in the control group. The changes of FBG in the lansoprazole group before and after treatment were significantly higher than those in the control group [(1.16 ± 0.62) vs (0.51 ± 0.45) mmol / 0.64 ± 0.50) vs (0.33 ± 0.43) mmol / L, P <0.05] than the control group (P <0.05). Correlation analysis showed that the increase of Gastrin in the lansoprazole group was associated with the decrease of HbA1C (r = -0.605, P <0.05). Conclusions Lansoprazole can improve metformin-induced gastric discomfort and decrease blood glucose level in T2DM patients, which may be related to the increase of Gastrin.